D-0735-2026 Class III Ongoing

Recalled by Ascend Laboratories, LLC — Bedminster, NJ

FDA drug recall D-0735-2026 was initiated by Ascend Laboratories, LLC on Jun 30, 2026 and is designated Class III. Reason for recall: Failed Impurities/Degradation Specifications: OOS result was observed during the related substance test analysis with respect to Impurity II, Impurity III and Total impurity testing for 12 Month… The recall status is ongoing. Affected quantity: 1,753 cartons.

Recall details

Product Type
Drugs
Report Date
Jul 29, 2026
Initiation Date
Jun 30, 2026
Voluntary/Mandated
Voluntary: Firm initiated
Product Quantity
1,753 cartons

Product description

Dabigatran etexilate Capsules, 110 mg, 60-count carton (6x10), Rx Only, Manufactured by: Alkem Laboratories, Mumbai, INDIA, Distributed by: Major Pharmaceuticals, Indianapolis, IN 46268, NDC 0904-7254-68.

Reason for recall

Failed Impurities/Degradation Specifications: OOS result was observed during the related substance test analysis with respect to Impurity II, Impurity III and Total impurity testing for 12 Month Long-Term Stability.

Distribution pattern

USA Nationwide

Code information

Lot: 25141707, Exp 4/30/2027.

Source

Dataset
openFDA drug recall enforcement reports
FDA record
This recall in openFDA (JSON)
Enforcement Report
Search FDA's Enforcement Report for D-0735-2026
openFDA file date
Nov 10, 2026
Loaded by RegDataLab
Nov 11, 2026

These dates say when openFDA published the data file and when RegDataLab last loaded it.

Source: openFDA record for D-0735-2026. Report a data issue: hello@regdatalab.com.